Dublin-based Endo International has made an unsolicited bid to acquire Salix Pharmaceuticals for about US$11 billion.
AbbVie, which terminated its deal to purchase Shire last year, has agreed to acquire Pharmacyclics for US$21 billion.
The current structure of most Canadian prior authorization (PA) programs is broken and needs to be fixed because traditional PA hasn’t changed in decades.
After failing to buy Allergan, Canada's Valeant Pharmaceuticals International has agreed to purchase Salix Pharmaceuticals for US$14.5 billion.
AstraZeneca has agreed to acquire the rights to Actavis’s branded respiratory business in Canada and the United States for US$600 million ($749 million).
Pfizer has agreed to buy Hospira for about US$17 billion ($21.3 billion) to boost its portfolio of injectable drugs and biosimilars.
Shire is reportedly looking at buying U.S.-based NPS Pharmaceuticals.
Merck has reached a deal to Cubist Pharmaceuticals for US$8.4 billion ($9.7 billion).
Canadian employers that use drug plan management strategies such as pay-direct cards, generic substitution or dispensing fee caps can realize significantly lower healthcare costs.
Provinces with age-based drug coverage should switch to income-based plans to head off serious financial pressure over the next few decades, says a C.D. Howe Institute report.